Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification

Blood

Volumn 126, Issue 4, 2015, Pages 454-462

  Strati, Paolo ^a   Shanafelt, Tait D ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; RITUXIMAB;

ANEMIA; AUTOIMMUNE DISEASE; BLOOD DONOR; BONE MARROW; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; EARLY CANCER; EVALUATION STUDY; FAMILY HISTORY; HIGH RISK PATIENT; HUMAN; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MEDICAL HISTORY; MONOCLONAL B CELL LYMPHOCYTOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN EXAMINATION; STEM CELL; THROMBOCYTOPENIA; TISSUES; ADULT; ANIMAL; B LYMPHOCYTE; DISEASE COURSE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; PATHOLOGY; RISK FACTOR;

ADULT; ANIMALS; B-LYMPHOCYTES; DISEASE PROGRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; RISK FACTORS;

EID: 84937847194     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-585059     Document Type: Review

References (110)

1. Hallek M, Cheson BD, Catovsky D, et al International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
2. Santos FP, O'Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? Cancer J. 2012;18(5):396-403.
3. Vogt RF, Shim YK, Middleton DC, et al. Monoclonal B-cell lymphocytosis as a biomarker in environmental health studies. Br J Haematol. 2007;139(5):690-700.
4. Shim YK, Vogt RF, Middleton D, et al. Prevalence and natural history of monoclonal and polyclonal B-cell lymphocytosis in a residential adult population. Cytometry B Clin Cytom. 2007;72(5):344-353.
5. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
6. Carney D. Peripheral blood lymphocytosis - what is the threshold for further investigation? Leuk Lymphoma. 2008;49(9):1659-1661.
7. Andrews JM, Cruser DL, Myers JB, Fernelius CA, Holm MT, Waldner DL. Using peripheral smear review, age and absolute lymphocyte count as predictors of abnormal peripheral blood lymphocytoses diagnosed by flow cytometry. Leuk Lymphoma. 2008;49(9):1731-1737.
8. Teggatz JR, Parkin J, Peterson L. Transient atypical lymphocytosis in patients with emergency medical conditions. Arch Pathol Lab Med. 1987;111(8):712-714.
9. Lesesve JF, Troussard X. Persistent polyclonal B-cell lymphocytosis. Blood. 2011;118(25):6485.
10. Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(8):837-851.
11. Karube K, Scarfò L, Campo E, Ghia P. Monoclonal B cell lymphocytosis and "in situ" lymphoma. Semin Cancer Biol. 2014;24:3-14.
12. Marti GE, Rawstron AC, Ghia P, et al International Familial CLL Consortium. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325-332.
13. Ghia P, Prato G, Scielzo C, et al. Monoclonal CD51 and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004;103(6):2337-2342.
14. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100(2):635-639.
15. Dagklis A, Fazi C, Sala C, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood. 2009;114(1):26-32.
16. Nieto WG, Almeida J, Romero A, et al Primary Health Care Group of Salamanca for the Study of MBL. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009;114(1):33-37.
17. Scarfò L, Dagklis A, Scielzo C, Fazi C, Ghia P. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer Biol. 2010;20(6):384-390.
18. Almeida J, Nieto WG, Teodosio C, et al Primary Health Care Group of Salamanca for the Study of MBL. CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults. Leukemia. 2011;25(4):718-722.
19. Goldin LR, Lanasa MC, Slager SL, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010;151(2):152-158.
20. Marti GE, Carter P, Abbasi F, et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2003;52(1):1-12.
21. Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100(7):2289-2290.
22. Matos DM, Ismael SJ, Scrideli CA, de Oliveira FM, Rego EM, Falcão RP. Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia. Br J Haematol. 2009;147(3):339-346.
23. Sellick GS, Goldin LR, Wild RW, et al. A highdensity SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007;110(9):3326-3333.
24. Slager SL, Rabe KG, Achenbach SJ, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011;117(6):1911-1916.
25. Crowther-Swanepoel D, Corre T, Lloyd A, et al. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. Blood. 2010;116(26):5957-5960.
26. Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol. 2009;147(4):444-449.
27. Fazi C, Dagklis A, Cottini F, et al. Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. Cytometry B Clin Cytom. 2010;78(Suppl 1):S61-S68.
28. Casabonne D, Almeida J, Nieto WG, et al Primary Health Care Group of Salamanca for the Study of MBL. Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. PLoS ONE. 2012;7(12):e52808.
29. Rawstron AC, Shanafelt T, Lanasa MC, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom. 2010;78(suppl 1):S19-S23.
30. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009;146(1):64-75.
31. Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009;27(24):3959-3963.
32. Dagklis A, Fazi C, Scarfo L, Apollonio B, Ghia P. Monoclonal B lymphocytosis in the general population. Leuk Lymphoma. 2009;50(3):490-492.
33. Henriques A, Rodríguez-Caballero A, Nieto WG, et al. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia. PLoS ONE. 2013;8(7):e67751.
34. Vardi A, Dagklis A, Scarfò L,etal. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 2013;121(22):4521-4528.
35. Ghia P, Fazi C, Pecciarini L, et al. CLL-like MBL in the general population persist over time, without clinical progression, though carrying the same cytogenetic abnormalities of CLL. Blood. 2010;116(21):1012-1013.
36. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575-583.
37. Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood. 2009;113(18):4188-4196.
38. Molica S, Mauro FR, Giannarelli D, et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica. 2011;96(2):277-283.
39. Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122(11):1891-1899.
40. Lionetti M, Fabris S, Cutrona G, et al. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol. 2014;165(5):629-639.
41. Rasi S, Monti S, Spina V, Foà R, Gaidano G, Rossi D. Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. Haematologica. 2012;97(1):153-154.
42. Greco M, Capello D, Bruscaggin A, et al. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis. Hematol Oncol. 2013;31(1):54-55.
43. Ojha J, Secreto C, Rabe K, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014;28(12):2395-2398.
44. Norman AD, Call TG, Hanson CA, et al. Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Olmsted county, 2000-2010: impact of the 2008 International Workshop on CLL Guidelines. Cancer Res. 2013;73(8).
45. Mulligan CS, Thomas ME, Mulligan SP. Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL). Blood. 2009;113(25):6496-6497, author reply 6497-6498.
46. Morabito F, Mosca L, Cutrona G, et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res. 2013;19(21):5890-5900.
47. Scarfò L, Zibellini S, Tedeschi A, et al. Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? Leukemia. 2012;26(7):1703-1707.
48. Oliveira AC, Fernandez de Sevilla A, Domingo A, et al. Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 x 10/L monoclonal lymphocytes better identifies subgroups with different outcomes. Ann Hematol. 2014;94(4):627-632.
49. te Raa GD, Tonino SH, Remmerswaal EB, et al. Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. Leuk Lymphoma. 2012;53(11):2321-2325.
50. Gentile M, Cutrona G, Fabris S, et al. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: results of the prospective, multicenter O-CLL1-GISL study. Am J Hematol. 2013;88(7):539-544.
51. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24(3):512-520.
52. Gibson SE, Swerdlow SH, Ferry JA, et al. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica. 2011;96(8):1144-1152.
53. Fox JP, Grignol VP, Gustafson J, et al. Incidental lymphoma during sentinel lymph node biopsy for breast cancer [abstract]. J Clin Oncol. 2010;28(15). Abstract e11083.
54. Herrick JL, Shanafelt TD, Kay NE, VanDyke DL, Morice WG, Hanson CA. Monoclonal B-cell lymphocytosis (MBL): a bone marrow study of an indolent form of chronic lymphocytic leukemia (CLL). Mod Pathol. 2008;21:256a.
55. Randen U, Tierens AM, Tjønnfjord GE, Delabie J. Bone marrow histology in monoclonal B-cell lymphocytosis shows various B-cell infiltration patterns. Am J Clin Pathol. 2013;139(3):390-395.
56. Rawstron AC. Occult B-cell lymphoproliferative disorders. Histopathology. 2011;58(1):81-89.
57. Winstanley AM, Sandison A, Bott SR, Dogan A, Parkinson MC. Incidental findings in pelvic lymph nodes at radical prostatectomy. J Clin Pathol. 2002;55(8):623-626.
58. Chu PG, Huang Q, Weiss LM. Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am Journal Surg Pathol. 2005;29(5):693-699.
59. Liu CL, Fan ST, Lo CM, et al. Hepatic resection for incidentaloma. J Gastrointest Surg. 2004;8(7):785-793.
60. He H, Cheng L, Weiss LM, Chu PG. Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. Leuk Lymphoma. 2007;48(10):1976-1980.
61. Fend F, Cabecadas J, Gaulard P, et al. Early lesions in lymphoid neoplasia: conclusions based on the Workshop of the XV meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden. J Hematop. 2012;5(3):169-199.
62. Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol. 2013;31(7):930-937.
63. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
64. Dreger P, Schetelig J, Andersen N, et al European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124(26):3841-3849.
65. Dreger P, Corradini P, Kimby E, et al Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12-17.
66. Perz JB, Ritgen M, Moos M, Ho AD, Kneba M, Dreger P. Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML. Bone Marrow Transplant. 2008;42(10):687-688.
67. Hardy NM, Grady C, Pentz R, et al. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol. 2007;139(5):824-831.
68. Ferrand C, Garnache-Ottou F, Collonge-Rame MA, et al. Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation. Eur J Haematol. 2012;88(3):269-272.
69. Rachel JM, Zucker ML, Fox CM, et al. Monoclonal B-cell lymphocytosis in blood donors. Br J Haematol. 2007;139(5):832-836.
70. Shim YK, Rachel JM, Ghia P, et al. Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood. 2014;123(9):1319-1326.
71. Brandt L, Brandt J, Olsson H, Anderson H, Moller T. Blood transfusion as a risk factor for non-Hodgkin lymphoma. Br J Cancer. 1996;73(9):1148-1151.
72. Cerhan JR, Wallace RB, Dick F, et al. Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2001;10(4):361-368.
73. Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):41-51.
74. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009;360(7):659-667.
75. Fazi C, Scarfò L, Pecciarini L, et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood. 2011;118(25):6618-6625.
76. Bennett FL, Dalal S, Jack AS, Hillmen P, Rawstron AC. Five-year follow-up of monoclonal B-cell lymphocytosis (MBL) in individuals with a normal blood count: expansion of the abnormal B-cell compartment but no progressive disease [abstract]. Blood. 2009;114(22). Abstract 30.
77. Fung SS, Hillier KL, Leger CS, et al. Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis. Leuk Lymphoma. 2007;48(6):1087-1091.
78. Kern W, Bacher U, Haferlach C, et al. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol. 2012;157(1):86-96.
79. Xu W, Li JY, Wu YJ, et al. Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis. Leuk Res. 2009;33(12):1619-1622.
80. Shanafelt TD, Kay NE, Rabe KG, et al. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia. 2012;26(2):373-376.
81. Molica S, Levato D, Dattilo A. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival. Haematologica. 1999;84(12):1094-1099.
82. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27(1):136-141.
83. Rodríguez-Caballero A, Henriques A, Criado I, et al. Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells. Br J Haematol. 2015;168(2):258-267.
84. Sanchez ML, Almeida J, Gonzalez D, et al. Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood. 2003;102(8):2994-3002.
85. Mansfield AS, Rabe KG, Slager SL, et al. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pract. 2014;10(1):e1-e4.
86. Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139(2):255-264.
87. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777-4787.
88. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.
89. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206.
90. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
91. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99(3):1023-1029.
92. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901.
93. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111(2):865-873.
94. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22(5-6):439-447.
95. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
96. Braggio E, Kay NE, VanWier S, et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia. 2012;26(7):1698-1701.
97. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679-4685.
98. Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011;29(31):4088-4095.
99. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49-62.
100. Dighiero G, Maloum K, Desablens B, et al French Cooperative Group on Chronic Lymphocytic Leukemia. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338(21):1506-1514.
101. Bergmann MA, Busch R, Eichhorst B, et al. Overall survival in early stage chronic lymphocytic leukemia patients with treatment indication due to disease progression: follow-up data of the CLL1 Trial of the German CLL Study Group [abstract]. Blood. 2013;122(21). Abstract 4127.
102. Schweighofer CD, Cymbalista F, Muller C, et al. Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia: first results of a randomized German-French cooperative phase III trial [abstract]. Blood. 2013;122(21). Abstract 524.
103. Brewer JD, Shanafelt TD, Otley CC, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012;30(8):843-849.
104. Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117(5):1492-1498.
105. Molica S, Digiesi G, Antenucci A, et al. Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). Leuk Res. 2012;36(4):443-447.
106. Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients - preliminary report. PLoS ONE. 2014;9(12):e114966.
107. Whitaker JA, Shanafelt TD, Poland GA, Kay NE. Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014;12(7):440-450.
108. Goldin LR, Björkholm M, Kristinsson SY, Turesson I, Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica. 2009;94(5):647-653.
109. Capalbo S, Trerotoli P, Ciancio A, Battista C, Serio G, Liso V. Increased risk of lymphoproliferative disorders in relatives of patients with B-cell chronic lymphocytic leukemia: relevance of the degree of familial linkage. Eur J Haematol. 2000;65(2):114-117.
110. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10):1204-1210.